EMA (EU)
GUIDANCE FINAL
Concept paper on revision of: Guideline on similar biological medicinal products, CHMP/437/04 Rev.1
Published: 7/22/2026Detected: 7/22/2026
Summary preview
Revises EMA’s biosimilar guideline framework to reflect post-2015 scientific progress, including a tailored clinical approach for comparative efficacy studies (CES) and ongoing alignment with the ICH M18 approach.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
clinical
manufacturing
quality
clinical
safety
labeling
#biosimilar
#comparative efficacy studies
#tailored clinical approach
#ICH M18
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026